Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTS-108
- Development stage
- Unknown
- Lead developer
- EpicentRx
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
DTS-108 is a water-soluble peptide-drug conjugate (PDC) consisting of SN-38, the active metabolite of the topoisomerase I inhibitor irinotecan, linked to a 20-amino acid human-derived oligopeptide via an esterase-sensitive cross-linker. Developed using Vectocell technology, the conjugate is designed to improve the solubility and delivery of SN-38. Upon administration, the linker is cleaved by endogenous esterases, releasing SN-38, which then inhibits DNA topoisomerase I, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells. DTS-108 was initially developed by Drais Pharmaceuticals and has been evaluated in Phase I clinical trials for the treatment of advanced solid tumors and malignancies.
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on DTS-108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTS-108.